Pharmaron Beijing Co Ltd (3759.HK)
Company Info
ISIN | CNE100003PG4 |
---|---|
Sector | Healthcare |
Industry | Biotechnology |
Highlights
Market Cap | HK$46.30B |
---|---|
EPS (TTM) | HK$1.14 |
PE Ratio | 11.55 |
Total Revenue (TTM) | HK$8.58B |
Gross Profit (TTM) | HK$2.92B |
Year Range | HK$7.98 - HK$24.85 |
Target Price | HK$16.87 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of HK$10,000 in Pharmaron Beijing Co Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Pharmaron Beijing Co Ltd had a return of -10.77% year-to-date (YTD) and -27.61% in the last 12 months.
Period | Return | Benchmark |
---|---|---|
Year-To-Date | -10.77% | 22.49% |
1 month | 43.24% | 3.72% |
6 months | 56.15% | 16.33% |
1 year | -27.61% | 33.60% |
5 years (annualized) | N/A | 14.41% |
10 years (annualized) | N/A | 11.99% |
Monthly Returns
The table below presents the monthly returns of 3759.HK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024 | -36.03% | 3.95% | -8.94% | 1.36% | 1.24% | -11.94% | 13.85% | -7.07% | 67.79% | -10.77% | |||
2023 | 6.00% | -23.52% | -24.94% | 2.73% | -14.62% | -16.26% | 27.91% | -9.63% | 1.86% | 0.11% | 1.29% | -16.30% | -55.34% |
2022 | -17.91% | -4.41% | 1.11% | 4.66% | -5.26% | 25.49% | -18.59% | -18.45% | -26.85% | -30.80% | 68.18% | 21.96% | -31.94% |
2021 | 13.89% | -11.13% | 10.78% | 9.67% | 15.39% | 11.57% | -17.83% | 1.47% | 7.94% | -9.02% | -5.19% | -25.14% | -7.99% |
2020 | 14.48% | 6.43% | -4.81% | 22.10% | 2.11% | 27.52% | 5.19% | 22.40% | -6.41% | 16.08% | -15.91% | 39.21% | 201.93% |
2019 | -0.71% | 3.69% | 2.96% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 3759.HK is 31, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Pharmaron Beijing Co Ltd (3759.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Pharmaron Beijing Co Ltd granted a 1.60% dividend yield in the last twelve months. The annual payout for that period amounted to HK$0.22 per share.
Period | TTM | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Dividend | HK$0.22 | HK$0.33 | HK$0.35 | HK$0.16 | HK$0.07 |
Dividend yield | 1.60% | 2.08% | 0.98% | 0.30% | 0.12% |
Monthly Dividends
The table displays the monthly dividend distributions for Pharmaron Beijing Co Ltd. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.22 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.22 | ||
2023 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.33 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.33 |
2022 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.35 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.35 |
2021 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.16 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.16 |
2020 | HK$0.07 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.07 |
Dividend Yield & Payout
Dividend Yield
Payout Ratio
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Pharmaron Beijing Co Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Pharmaron Beijing Co Ltd was 90.78%, occurring on Aug 23, 2024. The portfolio has not yet recovered.
The current Pharmaron Beijing Co Ltd drawdown is 84.28%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
---|---|---|---|---|---|---|
-90.78% | Jun 29, 2021 | 777 | Aug 23, 2024 | — | — | — |
-37.47% | Jan 26, 2021 | 29 | Mar 9, 2021 | 48 | May 20, 2021 | 77 |
-28.72% | Feb 18, 2020 | 25 | Mar 23, 2020 | 20 | Apr 22, 2020 | 45 |
-23.25% | Nov 10, 2020 | 15 | Nov 30, 2020 | 15 | Dec 21, 2020 | 30 |
-14.96% | Aug 31, 2020 | 9 | Sep 10, 2020 | 20 | Oct 12, 2020 | 29 |
Volatility
Volatility Chart
The current Pharmaron Beijing Co Ltd volatility is 57.78%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Pharmaron Beijing Co Ltd.
Loading data...
Income Statement
TTM | |
---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |